View:
Mini BasicThis view is available after user registration.
ShortThis view is available when you buy a license.
StandardThis view is available when you buy a license.
CompleteThis view is available when you buy a license.
Nivolumab 240, Head and Neck Tumors
Protocol-ID: 856 V2.0 (Mini), NIVO240, Head and Neck TumorsIndication(s)
- Head and Neck Tumors (Squamous Cell); ICD-10 C76.0
- Nasopharyngeal Carcinoma; ICD-10 C11.8, C11.9, C11.-
Links
- Nivolumab (opdivo) [EMA EPAR]
- Bristol-Myers Squibb’s Opdivo® (nivolumab) Now the First and Only FDA-Approved PD-1 Inhibitor to Offer Every Four-Week Dosing [URL]
 | The publishers and authors assume no liability for the accuracy of the contents. The application is at the own responsibility of the treating physician. ©Onkopti. |
Valid since: 12.06.2018